are glp-1 approved for weight loss The FDA has the first pill loss, a milestone in the growth of the revolutionary drugs. The drug, a once-a-day Wegovy tablet, is also approved for reducing cardiovascular Half of GLP-1 users ditch

Phenolics from dendrobium officinale leaf ameliorate dextran sulfate sodium-induced chronic colitis by regulating gut microbiota and intestinal barrier

Mechanistically, SQOR preserves intestinal homeostasis through two major pathways: it inhibits Drp1-mediated mitochondrial fission, thereby reducing ROS accumulation, and it activates the PGC1 pathway to promote mitochondrial biogenesis and antioxidant defenses (upregulating enzymes like GPX4 and SOD2)

FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)

[PubMed Citation] Fujita Y, Fujino Y, Onodera M, Kikuchi S, Kikkawa T, Inoue Y, Niitsu H, Takahashi K, Endo S